Compare LU & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LU | CRVS |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.9M | 843.7M |
| IPO Year | 2020 | 2016 |
| Metric | LU | CRVS |
|---|---|---|
| Price | $7.17 | $10.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $23.54 | ★ $31.50 |
| AVG Volume (30 Days) | 555.1K | ★ 893.7K |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $6.39 |
| 52 Week High | $9.60 | $26.95 |
| Indicator | LU | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 61.15 | 49.55 |
| Support Level | $1.38 | $9.40 |
| Resistance Level | $9.31 | $10.81 |
| Average True Range (ATR) | 0.61 | 0.67 |
| MACD | -0.30 | 0.13 |
| Stochastic Oscillator | 25.31 | 49.55 |
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.